Immunization studies for dengue serotype 2/4 vaccines using live-attenuated virus, adenoviral vector and envelope domain III fusion protein

Immunization studies for dengue serotype 2/4 vaccines using live-attenuated virus, adenoviral vector and envelope domain III fusion protein

碩士 === 國立清華大學 === 生物科技研究所 === 102 === 因申請專利緣故，資料延後公開

Bibliographic Details
Main Authors:	Tsai, Meng-Ju, 蔡孟如
Other Authors:	吳夙欽
Format:	Others
Language:	en_US
Published:	2014
Online Access:	http://ndltd.ncl.edu.tw/handle/9edqt9

Similar Items

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
by: César López-Camacho, et al.
Published: (2020-06-01)

Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III.
by: Guang-Hui Ji, et al.
Published: (2015-01-01)

Prime-boost immunization using adenovirus vector and envelope domain III protein fused with flagellin for tetravalent dengue vaccine development
by: Lin, Guan-Cheng, et al.
Published: (2013)

A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
by: Usha K. Nivarthi, et al.
Published: (2021-02-01)

Diagnostic Performance of Dengue Virus Envelope Domain III in Acute Dengue Infection
by: Ngoc Minh Nguyen, et al.
Published: (2019-07-01)

Development of Rotavirus Vaccine Using Adenoviral Vector
by: Chien-Wen Su, et al.
Published: (2005)

Using multivalent adenoviral vectors for HIV vaccination.
by: Linlin Gu, et al.
Published: (2013-01-01)

An Adenoviral Vector Based Vaccine for Rhodococcus equi.
by: Carla Giles, et al.
Published: (2016-01-01)

Domain Ⅲ of Dengue Virus Serotype 2 Envelope: Expression at High Levels in Escherichia coli and Competitive Inhibition of Virus Entry
by: Yang Yong- hong, et al.
Published: (2013-09-01)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).
by: Laura J White, et al.
Published: (2021-03-01)

T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.
by: Emily K Forbes, et al.
Published: (2012-01-01)

Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus
by: Indira S. Harahap-Carrillo, et al.
Published: (2015-07-01)

Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus
Published: (2015)

Development of flavivirus vaccine by using the adenoviral vector system
by: CHAO, YU-HUA, et al.
Published: (2019)

Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses
by: Lucas J. Kerstetter, et al.
Published: (2021-01-01)

Polytope Prediction for Dengue Vaccine Candidate Based on Conserved Envelope Glycoprotein of Four Serotypes of Dengue Virus and Its Antigenicity
by: Karimatul Himmah, et al.
Published: (2016-10-01)

Role of dengue viral envelope protein domain III in dengue induced coagulopathy and vasculopathy
by: Jhen-cheng Wu, et al.
Published: (2008)

Envelope exchange for the generation of live-attenuated arenavirus vaccines.
by: Andreas Bergthaler, et al.
Published: (2006-06-01)

Envelope Exchange for the Generation of Live-Attenuated Arenavirus Vaccines.
Published: (2006-06-01)

DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.
by: Adriana S Azevedo, et al.
Published: (2011-01-01)

Role of dengue virus envelope protein domain III in megakaryopoiesis suppression
by: Lin, Guan-Ling, et al.
Published: (2017)

Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis
by: Rafael G. Ferreira, et al.
Published: (2021-08-01)

Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines
by: Ekramy E. Sayedahmed, et al.
Published: (2020-10-01)

Ocular localization and transduction by adenoviral vectors are serotype-dependent and can be modified by inclusion of RGD fiber modifications.
by: Kazuhiro Ueyama, et al.
Published: (2014-01-01)

Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice
by: Ajit Kulkarni, et al.
Published: (2017-03-01)

Expression of Dengue virus envelope glycoproteins using a Measles vaccine vector
Published: (2013)

Molecular Changes in Dengue Envelope Protein Domain III upon Interaction with Glycosaminoglycans
by: James G. Hyatt, et al.
Published: (2020-11-01)

Dengue virus type-3 envelope protein domain III; expression and immunogenicity
by: Hossein Fahimi, et al.
Published: (2014-11-01)

Vaccination Potential Of Adenoviral Vectors Displaying Heterologous Epitopes In Their Capsid Proteins
by: Anchim, Aleksandra
Published: (2016)

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
by: Samir Andrade Mendonça, et al.
Published: (2021-08-01)

Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines
by: Lynda Coughlan
Published: (2020-05-01)

Development of recombinant adenoviral vectors as a pre-erythrocytic malaria vaccine
by: Sridhar, Saranya
Published: (2008)

Optimized Adenoviral Vector That Enhances the Assembly of FMDV O1 Virus-Like Particles in situ Increases Its Potential as Vaccine for Serotype O Viruses
by: Micaela Ziraldo, et al.
Published: (2020-11-01)

Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents
by: Joshua Del Papa, et al.
Published: (2017-01-01)

The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice.
by: Hsin-Wei Chen, et al.
Published: (2015-01-01)

Comparative immunogenicity and protective capacity of two Dengue-4 vaccine candidates based on P64k-envelope domain III
by: Laura Lazo, et al.

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
by: Hou, Jue, et al.
Published: (2022)

The persistence of recombinant adenoviral vectors
by: Jäger, Lorenz
Published: (2009)

Refocusing immune responses to dengue and Zika virus envelope protein domain III by immunizations and the studies of domain II fusion loop-associated cross-reactive antibodies
by: Lin, Hsiao-Han, et al.
Published: (2018)

Characterization of transgene expression in adenoviral vector-based HIV-1 vaccine candidates
by: Rolling Judith A, et al.
Published: (2010-02-01)

Cannot write session to /tmp/vufind_sessions/sess_hfabijj7502ltp7014877crh7v